Ken Griffin Harrow Health, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$20.85 - $46.47 $2.92 Million - $6.51 Million	-140,100 Reduced 41.29%	199,200 $8.96 Million
Q2 2024 Aug 14, 2024	BUY	$10.0 - $21.64 $2.62 Million - $5.68 Million	262,300 Added 340.65%	339,300 $7.09 Million
Q1 2024 May 15, 2024	BUY	$9.3 - $13.23 $351,540 - $500,094	37,800 Added 96.43%	77,000 $1.02 Million
Q4 2023 Feb 14, 2024	SELL	$8.1 - $16.36 $660,150 - $1.33 Million	-81,500 Reduced 67.52%	39,200 $439,000
Q3 2023 Nov 14, 2023	BUY	$14.03 - $22.08 $308,660 - $485,759	22,000 Added 22.29%	120,700 $1.73 Million
Q2 2023 Aug 14, 2023	BUY	$17.37 - $28.08 $1.23 Million - $1.99 Million	70,800 Added 253.76%	98,700 $1.88 Million
Q1 2023 May 15, 2023	BUY	$13.84 - $21.46 $85,808 - $133,052	6,200 Added 28.57%	27,900 $590,000
Q4 2022 Feb 14, 2023	BUY	$10.28 - $14.78 $97,660 - $140,410	9,500 Added 77.87%	21,700 $320,000
Q3 2022 Nov 14, 2022	BUY	$6.57 - $24.88 $9,198 - $34,832	1,400 Added 12.96%	12,200 $147,000

176

21.4M

845K

717K

Ticker HROW
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 27,070,000
Market Cap $1.06B
Description
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.